ePrints

Immune checkpoint inhibitor-induced inflammatory arthritis

Lookup NU author(s): Dr Arthur PrattORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© 2025 The Author(s). Immune checkpoint inhibitors (ICI) used for the treatment of malignancy are associated with immune-related adverse events, which include inflammatory arthritis. ICI-induced inflammatory arthritis (ICI-IA) is a new clinical entity that may lead to functional impairment and may be persistent even after ICI cessation. We discuss the clinical features, investigation and differential diagnosis. Management needs to consider the safety of immunosuppression in the context of the underlying cancer, and current practice will be further informed by ongoing clinical trials.

Publication metadata

Author(s): Fisher BA, Allard A, Dubey S, Mankia K, Pratt AG, Pallan L

Publication type: Review

Publication status: Published

Journal: Clinical Medicine

Year: 2025

Volume: 25

Issue: 5

Print publication date: 01/09/2025

Online publication date: 06/08/2025

Acceptance date: 31/07/2025

ISSN (print): 1470-2118

ISSN (electronic): 1473-4893

Publisher: Elsevier B.V.

URL: https://doi.org/10.1016/j.clinme.2025.100496

DOI: 10.1016/j.clinme.2025.100496

PubMed id: 40774545

Share